Compare iShares MSCI France ETF (EWQ) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Stryker Corporation — how do they compare? iShares MSCI France ETF trades at $47.49, while Stryker Corporation trades at $345.59 (market cap $133.54B). The key difference: Stryker Corporation pays a 1.01% dividend while iShares MSCI France ETF pays none, and iShares MSCI France ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| EWQ | SYK | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $48.35 | $394.34 |
52-Week Low | $41.68 | $282.58 |
Market Cap | — | $133.54B |
Enterprise Value | — | $145.01B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ (iShares MSCI France ETF) trades at $47.51, down 0.5% on the day, with a bullish technical signal driven by moving averages. The ETF offers exposure to French equities with a 15.3x P/E ratio and favorable PEG of 1.6x according to Seeking Alpha (August 4, 2026). Recent institutional activity shows Allspring Global reduced its position by 26.2% in Q1 2026, while European central bank policy remains a key market driver.
The outlook for EWQ remains positive with French stocks hitting new highs and attractive valuations supporting further upside. Key risks include ECB monetary policy uncertainty amid Middle East tensions and potential production constraints at French nuclear facilities. The concentrated industrial sector exposure (32%) provides growth potential but increases sector-specific vulnerability.
Stryker (SYK) trades at $347.21, up 0.4% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, including a 9% organic sales growth in Q2 2026 and a net income margin of 14.43%. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS, expanding its robotic surgery portfolio. Analyst consensus is overwhelmingly positive, with 74% recommending Buy and a price target of $379.44.
The outlook for SYK is favorable, driven by robust earnings growth and strategic product launches. Key risks include cybersecurity vulnerabilities and margin pressures from tariffs. With no sell ratings and strong institutional support, the stock presents a compelling opportunity for growth-oriented investors, though monitoring quarterly execution remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
